The purpose of this study is to investigate potential metabolic effects of resveratrol in morbidly obese women undergoing gastric bypass surgery. The investigators hypothesize that resveratrol will: * Decrease hepatic very-low-density-lipoprotein-triglyceride (VLDL-TG) secretion * Decrease hepatic and adipose tissue VLDL-TG uptake * Increase insulin sensitivity The investigators will look at changes in: * Lipid turnover (VLDL-TG kinetics, palmitate kinetics,calorimetry) * VLDL-TG uptake in different tissues (subcutaneous femoral adipose tissue, subcutaneous abdominal adipose tissue, visceral adipose tissue and liver tissue) * Insulin sensitivity (glucose kinetics during hyperinsulinaemic euglycaemic clamp) * Regulation of liver fat handling * Lipoprotein lipase activity and fat cell size (abdominal and femoral adipose tissue)
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
TRIPLE
Enrollment
16
500mg 3 times daily for 1 month
1 placebo tablet 3 times daily for 1 month
Department of Endocrinology and Internal Medicine
Aarhus C, Denmark
Hepatic VLDL-TG secretion and peripheral VLDL-TG clearance
\- changes from baseline after treatment with either resveratrol or placebo
Time frame: 1 month
Hepatic and adipose VLDL-TG uptake
\- changes in VLDL-TG uptake in resveratrol group and placebo group
Time frame: 1 month
Basal and insulin stimulated free fatty acid (FFA) and glucose turnover
\- changes from baseline after treatment with either resveratrol or placebo
Time frame: 1 month
VLDL-TG oxidation
\- changes from baseline after treatment with either resveratrol or placebo
Time frame: 1 month
Regulation of liver fat handling
\- changes in regulation of liver fat handling in resveratrol group and placebo group
Time frame: 1 month
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.